Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.

Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ.

J Transl Med. 2014 Jun 25;12:183. doi: 10.1186/1479-5876-12-183.

PMID:
24962263
[PubMed - in process]
Free Article
2.

Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.

Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lee S, Gane EJ.

Gastroenterology. 2014 May;146(5):1240-8. doi: 10.1053/j.gastro.2014.01.044. Epub 2014 Jan 23.

PMID:
24462735
[PubMed - indexed for MEDLINE]
3.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
[PubMed - indexed for MEDLINE]
4.

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.

Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF.

J Hepatol. 2013 Oct;59(4):709-16. doi: 10.1016/j.jhep.2013.06.007. Epub 2013 Jun 17.

PMID:
23792029
[PubMed - indexed for MEDLINE]
5.

[Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].

Zhu YY, Wu YL, Chen J, Zheng Q, Dong J, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Oct;20(10):737-41. doi: 10.3760/cma.j.issn.1007-3418.2012.10.006. Chinese.

PMID:
23207332
[PubMed - indexed for MEDLINE]
6.

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.

Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F.

Antivir Ther. 2013;18(4):623-33. doi: 10.3851/IMP2555. Epub 2013 Mar 13.

PMID:
23486701
[PubMed - indexed for MEDLINE]
7.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

PMID:
16904047
[PubMed - indexed for MEDLINE]
Free Article
8.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F.

Gastroenterology. 2011 Jan;140(1):132-43. doi: 10.1053/j.gastro.2010.10.011. Epub 2010 Oct 16.

PMID:
20955704
[PubMed - indexed for MEDLINE]
9.

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.

Gastroenterology. 2012 Sep;143(3):619-28.e1. doi: 10.1053/j.gastro.2012.05.037. Epub 2012 May 27.

PMID:
22643350
[PubMed - indexed for MEDLINE]
10.

[A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].

Yu SL, Guo CY.

Zhonghua Gan Zang Bing Za Zhi. 2013 Apr;21(4):267-70. doi: 10.3760/cma.j.issn.1007-3418.2013.04.007. Chinese.

PMID:
24021787
[PubMed - in process]
11.

Clinical implications of hepatitis B surface antigen quantitation in the natural history of chronic hepatitis B virus infection.

Tan Z, Li M, Kuang X, Tang Y, Fan Y, Deng G, Wang Y, He D.

J Clin Virol. 2014 Apr;59(4):228-34. doi: 10.1016/j.jcv.2014.01.013. Epub 2014 Jan 26.

PMID:
24529415
[PubMed - in process]
12.

Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.

Lu H, Geng da Y, Shen F, Zhang JY, Lu B, Ma LX.

Virol J. 2011 Sep 21;8:444. doi: 10.1186/1743-422X-8-444.

PMID:
21936898
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].

Yue W, Yuan H, Mao XR, Deng YD, Chen L.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):184-8. Chinese.

PMID:
23967738
[PubMed - indexed for MEDLINE]
14.

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers.

Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA.

Hepatology. 2010 Jun;51(6):1933-44. doi: 10.1002/hep.23571.

PMID:
20512987
[PubMed - indexed for MEDLINE]
15.

Relevance of hepatitis B surface antigen levels in patients with chronic hepatitis B during 5 year of tenofovir treatment.

Singh AK, Sharma MK, Hissar SS, Gupta E, Sarin SK.

J Viral Hepat. 2014 Jun;21(6):439-46. doi: 10.1111/jvh.12149. Epub 2013 Aug 26.

PMID:
24750522
[PubMed - in process]
16.

Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.

Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.

Am J Gastroenterol. 2011 Oct;106(10):1766-73. doi: 10.1038/ajg.2011.253. Epub 2011 Aug 9.

PMID:
21826112
[PubMed - indexed for MEDLINE]
17.

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.

Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.

J Viral Hepat. 2012 Oct;19(10):724-31. doi: 10.1111/j.1365-2893.2012.01599.x. Epub 2012 Mar 15.

PMID:
22967104
[PubMed - indexed for MEDLINE]
18.

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.

Lee MH, Lee da M, Kim SS, Cheong JY, Cho SW.

J Med Virol. 2011 Jul;83(7):1178-86. doi: 10.1002/jmv.22089.

PMID:
21567421
[PubMed - indexed for MEDLINE]
19.

Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.

Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD.

World J Gastroenterol. 2010 Aug 28;16(32):4095-9.

PMID:
20731026
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.

Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P.

J Hepatol. 2011 Jul;55(1):61-8. doi: 10.1016/j.jhep.2010.10.027. Epub 2010 Dec 5.

PMID:
21145875
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk